MoonLake's Week 40 HS Data Offers Durability Glimmer Amid Lingering Regulatory and Liquidity Risks

What happened

MoonLake announced Week 40 results from its Phase 3 VELA trials for sonelokimab in hidradenitis suppurativa, presented at the 2026 AAD meeting, but this long-term data comes after mixed 2025 topline outcomes where one trial missed its primary endpoint due to placebo variability. The DeepValue report highlights that this placebo issue shifted the thesis toward regulatory risk, with the company now relying on pooled and treatment-policy analyses for approval, which regulators may not accept. Week 40 data likely shows consistent active-arm performance, as previously noted, but it does not directly address the elevated placebo rate that caused the Phase 3 miss, leaving approvability uncertain. Liquidity remains a critical concern, with near-zero cash reported mid-2025 and reliance on non-dilutive financing, raising execution risks for this single-asset story. Investors should temper optimism, as the key swing factors—regulatory feedback on analyses, full 52-week durability outcomes, and PsA Phase 3 readouts in 2026—remain unresolved and essential for re-rating the equity.

Implication

This long-term data reinforces the consistency of sonelokimab's active-arm responses in HS, which could marginally bolster regulatory discussions on pooled analyses, yet it does not solve the core issue of placebo variability that jeopardized the Phase 3 program. Durability at 40 weeks is a positive signal, but full 52-week outcomes in 2026 are necessary to confirm long-term benefits and meet payer expectations for robust endpoints. Liquidity constraints, with cash nearly depleted in mid-2025, amplify execution risk, making any regulatory delays or need for additional trials potentially devastating. Competitive pressure in HS from approved IL-17 inhibitors like bimekizumab means MoonLake must demonstrate clear superiority or durability advantages to gain market share, which remains unproven. Ultimately, while the data keeps multi-indication optionality alive, investors should hold until 2026 catalysts provide clearer regulatory and clinical pathways, as the current risk/reward skew is unfavorable for chasing gains.

Thesis delta

The Week 40 announcement does not shift the fundamental thesis; it underscores the ongoing reliance on regulatory acceptance of pooled analyses for adult HS approval, which remains uncertain. Durability evidence from this data is encouraging but insufficient to alter the HOLD/NEUTRAL stance, as liquidity risks and pending 2026 readouts in HS and PsA are the true swing factors for any upgrade or downgrade.